Published 09/18/2024 9:44:26 p.m.

Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer

Summary by MedPage Today

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced

0 Articles

All

Left

Center

Right

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated09/19/2024 5:19:21 a.m.Bias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)